Pages that link to "Q34803308"

The following pages link to Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis (Q34803308):

Displaying 47 items.

• Calcium intake and bone mineral density: systematic review and meta-analysis (Q26784337) (← links)
• Loss of life years after a hip fracture (Q33660935) (← links)
• Plate on plate osteosynthesis for the treatment of nonhealed periplate fractures (Q33710623) (← links)
• Treating postmenopausal osteoporosis in women at increased risk of fracture - critical appraisal of bazedoxifene: a review (Q34271979) (← links)
• Management of osteoporosis in patients hospitalized for hip fractures (Q34284002) (← links)
• Prevention and treatment of postmenopausal osteoporosis (Q34296614) (← links)
• Vitamin D in health and disease: Current perspectives (Q34481617) (← links)
• Sex and gender considerations in male patients with osteoporosis (Q35036493) (← links)
• Review of ibandronate in the treatment of osteoporosis (Q35076601) (← links)
• The Evidence for Efficacy of Osteoporosis Treatment in Men with Primary Osteoporosis: A Systematic Review and Meta-Analysis of Antiresorptive and Anabolic Treatment in Men (Q35110262) (← links)
• Strategies for the prevention of hip fracture (Q35216413) (← links)
• Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents (Q35229871) (← links)
• Baseline age and time to major fracture in younger postmenopausal women (Q35542877) (← links)
• Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant (Q35663909) (← links)
• Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities (Q35775369) (← links)
• Osteoporotic fracture and parathyroid hormone (Q35825410) (← links)
• Teriparatide (1-34 human PTH) regulation of osterix during fracture repair (Q35915566) (← links)
• Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis (Q36045845) (← links)
• Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies (Q36178344) (← links)
• Skeletal and nonskeletal effects of raloxifene (Q36203250) (← links)
• Benefit-risk assessment of raloxifene in postmenopausal osteoporosis (Q36209607) (← links)
• Anti-vertebral fracture efficacy of raloxifene: a meta-analysis (Q36283117) (← links)
• Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. (Q36585100) (← links)
• BMD screening in older women: initial measurement and testing interval (Q36630230) (← links)
• Patient adherence to osteoporosis medications: problems, consequences and management strategies. (Q36711181) (← links)
• Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence (Q36763643) (← links)
• The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy (Q36829073) (← links)
• Prevention of osteoporosis-related fractures among postmenopausal women and older men. (Q37428448) (← links)
• Use of combination therapy in the treatment of primary osteoporosis: protocol for a network meta-analysis of randomised trials (Q37454589) (← links)
• Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines (Q37911560) (← links)
• Antiresorptive therapies for osteoporosis: a clinical overview (Q37926914) (← links)
• Effects of increasing age, dosage, and duration of PTH treatment on BMD increase--a meta-analysis. (Q37975163) (← links)
• Emerging drugs for osteoporosis (Q38226342) (← links)
• Agreement between fragility fracture risk assessment algorithms as applied to adults with chronic spinal cord injury (Q40162458) (← links)
• Osteoporosis guidelines. (Q42875457) (← links)
• Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis. (Q43950222) (← links)
• Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International (Q44818567) (← links)
• The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug. (Q48322047) (← links)
• Responses of Urinary N-Telopeptide and Renal Calcium Handling to PTH Infusion after Treatment with Estrogen, Raloxifene, and Tamoxifen (Q53669167) (← links)
• Osteoporosis (Q57417202) (← links)
• The effectiveness of intermittent rat parathyroid hormone (1-34) treatment on low bone mass due to oestrogen or androgen depletion in skeletally mature rats (Q58294828) (← links)
• There are reasons to continue hormone replacement therapy longer than 10 years (Q73326745) (← links)
• Osteoporosis (Q79299225) (← links)
• [Should the menopause be treated?] (Q79780869) (← links)
• [Postmenopausal and steroid-induced osteoporosis guideline-orientated prevention and treatment] (Q81649648) (← links)
• Transiliac bone biopsy in osteoporosis: frequency, indications, consequences and complications. An evaluation of 99 consecutive cases over a period of 14 years (Q81783048) (← links)
• The Importance of Physicians’ Risk Perception in Osteoporosis Treatment Decision Making (Q82462708) (← links)